| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | -13.29% | Jefferies | → $3 | Downgrades | Hold → Underperform |
| 03/03/2022 | -78.32% | Jefferies | $5 → $0.75 | Downgrades | Buy → Hold |
| 03/03/2022 | 15.61% | RBC Capital | $5 → $4 | Maintains | Outperform |
| 09/24/2021 | 73.41% | RBC Capital | → $6 | Initiates Coverage On | → Outperform |
What is the target price for Avalo Therapeutics (AVTX)?
The latest price target for Avalo Therapeutics (NASDAQ: AVTX) was reported by Jefferies on February 8, 2023. The analyst firm set a price target for $3.00 expecting AVTX to fall to within 12 months (a possible -13.29% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avalo Therapeutics (AVTX)?
The latest analyst rating for Avalo Therapeutics (NASDAQ: AVTX) was provided by Jefferies, and Avalo Therapeutics downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for Avalo Therapeutics (AVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
Is the Analyst Rating Avalo Therapeutics (AVTX) correct?
While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a downgraded with a price target of $0.00 to $3.00. The current price Avalo Therapeutics (AVTX) is trading at is $3.46, which is out of the analyst's predicted range.